Pharma BD Deal Intelligence
Greatest ROI in pharma history: $6.9B purchase yielded $231B in Humira revenue
Full analysis, sources & comparables →Abbott to buy Knoll for $6.9 billion, acquiring BASF's pharmaceutical business including the promising monoclonal antibody D2E7.
Abbott Laboratories SEC filing related to the definitive agreement to acquire the pharmaceutical business of BASF (Knoll).
Abbott acquired adalimumab (D2E7, later branded Humira) when it purchased Knoll Pharmaceuticals from BASF in 2001 for $6.9 billion, gaining what would become…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Abbott Laboratories acquired the global pharmaceutical operations of BASF (Knoll Pharmaceuticals) for $6.9 billion in cash. The deal included D2E7, a developmental monoclonal antibody later known as Humira (adalimumab), which became the world's best-selling drug with peak annual sales exceeding $20 billion.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Abbott Laboratories / Knoll Pharmaceuticals (BASF Pharma) (this deal) | 2000 | $6.9B | 95 |
| Abbott Laboratories / Knoll Pharmaceutical Company (BASF Pharma) | 2001 | $6.9B | 100 |
| Abbott Laboratories / Alere Inc. | 2016 | $5.8B | 95 |
| Abbott Laboratories / St. Jude Medical | 2016 | $30.5B | 82 |
| Abbott Laboratories / TheraSense Inc. | 2004 | $1.2B | 81 |
| Abbott Laboratories / Vysis Inc. | 2001 | $355M | 79 |
| Abbott Laboratories / Genentech, Inc. (Roche Group) | 2007 | — | 79 |
← Browse all deals · How we score deals
More: 2000 deals · Abbott Laboratories deals · Cardiovascular deals